Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04979247 · ClinicalTrials.gov registry record · Phase 4
Intravenous Oliceridine and Opioid-related Complications
A Phase 4 study, sponsored by The Cleveland Clinic.
- Completed
- Registry status
- Phase 4
- Development phase
- 204
- Enrollment target
NCT04979247: Completed Phase 4 study, sponsored by The Cleveland Clinic.
NCT04979247 is a Phase 4 study that has completed, run by The Cleveland Clinic. The registered enrollment target is 204 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (61% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04979247, a Phase 4 study, has completed, sponsored by The Cleveland Clinic.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 204 participants
- Enrollment target
Study Summary
The investigator will evaluate the side effects of oliceridine.
Primary Outcome
Occurrence of clinically meaningful respiratory compromise events i.e. SpO2 ≤ 85 % for ≥3 min, etPCO2 ≤ 15 mmHg; ≥ 3 min, RR ≤ 5 bpm for ≥3 min, Apnea Event \>30 s
Interventions
- DRUG Oliceridine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 204 participants |
| Start Date | 2021-09-15 |
| Est. Completion | 2024-01-10 |
| Phase | Phase 4 |
What the finished NCT04979247 record still lists
NCT04979247 is an interventional study that assigns participants to a tested intervention. The registered 204 participants enrollment target is mid-sized for trials with a published cap, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (61% lower).
The record links to 0 conditions, and to 1 intervention - of which Oliceridine is the first listed.
NCT04979247 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04979247 about?
NCT04979247 is a clinical study titled "Intravenous Oliceridine and Opioid-related Complications". The investigator will evaluate the side effects of oliceridine.
What is the current status of trial NCT04979247?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 204 participants. The study started on 2021-09-15. Estimated completion is 2024-01-10.
What interventions are being tested in trial NCT04979247?
The interventions under investigation include: Oliceridine (DRUG).
Who is sponsoring clinical trial NCT04979247?
This trial is sponsored by The Cleveland Clinic, which has 688 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04979247's enrollment target sits among peer trials
204 402nd of 2000 higher than 1,598 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03481010 · 204 participants · NA
Periacetabular Osteotomy With and Without Arthroscopic Management of Central Compartment Pathology
- NCT04249830 · 204 participants · NA
Stem Cell Transplant From Donors After Alpha Beta Cell Depletion in Children and Young Adults
- NCT04503395 · 204 participants · NA
ShOrt neCK AAA RAndomized Trial - ESAR and FEVAR: SOCRATES
- NCT04793776 · 204 participants · NA
Manage Emotions to Reduce Aggression (MERA)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI